CIK 0001370053
- Non-accelerated filer
- Smaller reporting company
ANAPTYSBIO, INC
Sign in to watch- Ticker
- ANAB
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Jun 30
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 203828755
- Phone
- +1 858-362-6295
- Business address
- 10770 WATERIDGE CIRCLE, SUITE 210, SAN DIEGO, CA, 92121
- Former names
- ANAPTYSBIO INC, ANAPTYS BIOSCIENCES INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $249,372
- in 1 filing, $249K under 10b5-1 plans
Net −$249,372. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 67 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2022-06-08 | LOUMEAU ERIC J COO, General Counsel | Sale | −2,500 | $24.00 | $60K | 523 |
| 2022-06-08 | LOUMEAU ERIC J COO, General Counsel | Exercise or conversion · Employee Stock Option (Right to Buy) | −2,500 | 83,000 | ||
| 2022-05-18 | LOUMEAU ERIC J COO, General Counsel | Sale | −1,146 | $20.50 | $23K | 523 |
| 2022-05-05 | EcoR1 Capital, LLC 10% owner | Purchase | +668,237 | $21.63 | $14.5M | 7,521,024 |
| 2022-05-05 | EcoR1 Capital, LLC 10% owner | Sale | −668,237 | $21.63 | $14.5M | 7,521,024 |
| 2022-03-21 | Faga Daniel Interim CEO | Grant or award | +887,043 | 887,043 | ||
| 2022-02-10 | Lizzul Paul F. Chief Medical Officer | Grant or award · Stock Option (right to buy) | +70,000 | 70,000 | ||
| 2022-02-10 | Marquet Magda Director | Grant or award · Stock Option (right to buy) | +9,200 | 9,200 | ||
| 2022-02-10 | Hamill Laura Director | Grant or award · Stock Option (right to buy) | +9,200 | 9,200 | ||
| 2022-02-10 | Topper James N Director | Grant or award · Stock Option (right to buy) | +9,200 | 9,200 | ||
| 2022-02-10 | Schmid John P. Director | Grant or award · Stock Option (right to buy) | +9,200 | 9,200 | ||
| 2022-02-10 | Suria Hamza President, CEO | Grant or award · Stock Option (right to buy) | +200,000 | 200,000 | ||
| 2022-02-10 | RENTON HOLLINGS Director | Grant or award · Stock Option (right to buy) | +9,200 | 9,200 | ||
| 2022-02-10 | LOUMEAU ERIC J COO, General Counsel | Grant or award · Stock Option (right to buy) | +70,000 | 70,000 | ||
| 2022-02-10 | MULROY DENNIS Chief Financial Officer | Grant or award · Stock Option (right to buy) | +70,000 | 70,000 | ||
| 2022-02-10 | FENTON DENNIS M Director | Grant or award · Stock Option (right to buy) | +9,200 | 9,200 | ||
| 2022-02-10 | Faga Daniel Director | Grant or award · Stock Option (right to buy) | +9,200 | 9,200 | ||
| 2022-02-10 | Ware J. Anthony Director | Grant or award · Stock Option (right to buy) | +9,200 | 9,200 | ||
| 2021-12-20 | Suria Hamza President, CEO | Exercise or conversion | +36,645 | $1.12 | $41K | 105,245 |
| 2021-12-20 | Suria Hamza President, CEO | Sale | −11,915 | $34.89 | $416K | 93,330 |
Page 22 of 27 · 522 trades